As part of our mission to eliminate cancer, Torrance Memorial Hunt Cancer
Institute physicians conduct several clinical trials to test new treatments
for both common and rare cancers. Look through our clinical trials list
to find studies for which you may be eligible.
Hunt Cancer Institute Active Clinical Trials
These studies are currently enrolling participants.
Disease |
Title |
Summary |
Status |
Investigator |
Breast Cancer |
CONTESSA: ODO-TE-B301A. Odonate/inVentive |
Phase 3 Study of Tesetaxel(PO) plus reduced dose of Capecitabine(PO) vs
Capecitabine alone in patients with HR (+), HER2 (-), locally advanced
or metastatic breast cancer, previously treated with a taxane. |
Open/Active |
Swati Sikaria, MD |
Breast Cancer |
EMERALD: RAD1901-308 |
ELACESTRANT MONOTHERAPY VS. STANDARD OF CARE (ENDOCRINE THERAPY) FOR THE
TREATMENT OF PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER FOLLOWING
CDK4/6 INHIBITOR THERAPY: A PHASE 3 RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED,
MULTICENTER TRIAL. |
Open/Active |
David Chan, MD |
Colorectal Cancer |
NOVA:CG001, Clinical Genomics/Beaufort |
Only one blood collection is required for enrollment. Followed by ONE scan/test
(CT/MRI/PET/endoscopy). Must be in remission from Stage II/III CRC and
within 6 mos-24 months after treatment, with no evidence of disease, no
other current cancer. Blood draw to be done within 6 months prior to scan,
or on day of, but not after contrast agents. |
Open/Active |
David Chan, MD |
GI Cancer |
PASCAL: CG013, Clinical Genomics/Beaufort |
Enrolling reoccurrance arm only. Only one blood collection is required
within 4 weeks of SCAN. Must be in remission from Stage II/III CRC and
within 6 mos-24 months after treatment, with no evidence of disease, no
other current cancer. Coincides with NOVA. |
Open/Active |
David Chan, MD |
Lung Cancer |
VISION: MS200095-0022 Merck/Quintiles |
Pre-screening site only. Phase II 2nd/3rd line – Stage IV NSCLC-
all histology included- ALK/EGFR Negative. Must not have received more
than two lines of therapy. Seeking archival tissue for MET exon 14 testing***.
MET AMP/MET exon 14 testing is available using Guardant 360 blood draw.
Either archival tissue and/or Guardant may be used, MD discretion.
***If positive for MET AMP/exon 14 then pt will be referred to City of
Hope for treatment arm of trial.
|
Open/Active |
Andrew Horodner, MD |
All Solid Tumors |
LexentBio: LB-1985106 |
All solid tumors. No lymphoma or heme. Currently enrolling ONLY New Dx/Progression-
UNRESECTABLE. Patients will be enrolled before the start of any new therapy
(targeted, endocrine, chemotherapy, radiation, etc.) Blood (20mLs-2 tubes)
will be collected before the start of any treatment and collected every
3-4 weeks depending on treatment cycle. Subject can stay on study until
progression, etc. |
Open/Active |
David Chan, MD |
Active Trials - UCLA Trials
The following clinical trials are available at Torrance Memorial Physician
Network Cancer Care and are in coordination with the
TRIO-US / Clinical Trials Network.
Disease |
Title |
Summary |
Status |
Investigator |
Breast Cancer ‐ ADJUVANT (ER +, HER2 neg) |
TRIO 033 ‐ Novartis CLEE011O12301C "NATALEE" |
Phase III, multicenter, randomized, open‐label trial to evaluate efficacy
and safety of ribociclib with endocrine therapy as an adjuvant treatment
in patients with hormone receptor‐positive, HER2‐negative, early breast
cancer (New Adjuvant Trial with Ribociclib.[LEE011]:NATALEE) |
Open/Active |
David Chan, MD |
Pancreatic Cancer |
ARMO AM0010‐301 SEQUOIA |
A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared
with FOLFOX Alone as Second‐line Therapy in Patients with Metastatic Pancreatic
Cancer that has Progressed During or Following a First‐Line Gemcitabine
Containing Regimen |
Open/Active |
Hugo Hool, MD |
Colorectal Cancer |
Abbvie M14‐064 |
Phase 2 Study Comparing Efficacy and Safety of ABT‐165 plus FOLFIRI vs
Bevacizumab plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated
with Fluoropyrimidine/Oxaliplatin and Bevacizumab. |
Open/Active |
Thomas Lowe, MD |
Lymphoma |
Incyte INCB 50465‐204 (CITADEL‐204) |
Open Label 2‐Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects
With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior
Exposure to a BTK Inhibitor. |
Open/Active |
Swati Sikaria, MD |
Lung Cancer |
BMS CA209‐817 NSCLC (CHECKMATE 817) |
A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with
Ipilimumab in Participants with Advanced Lung Malignancies. |
Open/Active |
Thomas Lowe, MD |
Other |
BMS 209‐655 |
Hodgkin lymphoma molecular profiling and clinical outcomes in U.S Community
oncology practice. |
Open/Active |
Hugo Hool, MD |
Cedars-Sinai Trials
Disease |
Title |
Summary |
Status |
Investigator |
DCIS/Breast Cancer |
COMET AFT-25 |
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial
For Low Risk DCIS: A Phase III Prospective Randomized Trial. |
Open/Active |
Swati Sikaria, MD |
Urology/Renal Cell Carcinoma |
CANTATA- CX-839-008 |
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing
CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib
(Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC). |
Open/Active |
Vanessa Dickey, MD |
Basket Trial |
TAPUR- ASCO |
TESTING THE USE OF FDA APPROVED DRUGS THAT TARGET A SPECIFIC ABNORMALITY
IN A TUMOR GENE IN PEOPLE WITH ADVANCED STAGE CANCER. |
Open/Active |
Swati Sikaria, MD |
For More Information
For more information about the clinical trials at Torrance Memorial, call
310-517-7077.